復(fù)發(fā)性阿弗他潰瘍患者可溶性程序性死亡受體1及可溶性程序性死亡配體1表達與免疫功能的相關(guān)性
發(fā)布時間:2019-05-29 08:41
【摘要】:目的了解復(fù)發(fā)性阿弗他潰瘍(RAU)患者血清中可溶性程序性死亡受體-1(s PD-1)、可溶性程序性死亡配體-1(s PD-L1)蛋白表達與患者免疫功能狀態(tài)的相關(guān)性,探討s PD-1/s PD-L1在RAU免疫發(fā)病機制中的作用及意義。方法研究對象為30例RAU患者(輕型18例,重型5例,皰疹型7例)及18例健康人(對照組)。采用流式細胞術(shù)檢測RAU患者外周血細胞免疫指標(CD3+、CD4+、CD8+、CD19+、CD16++56+),散射比濁法檢測RAU患者體液免疫指標(Ig G、Ig A、Ig M、C3、C4),酶聯(lián)免疫吸附測定RAU患者及健康人血清中s PD-1、s PD-L1蛋白表達,并對s PD-1、s PD-L1表達水平與RAU患者免疫功能狀況及臨床特征的相關(guān)性進行分析。結(jié)果與正常值相比,RAU患者CD4+水平降低,Ig M水平增高,差異有統(tǒng)計學(xué)意義(P0.05)。RAU患者的s PD-1及s PD-L1蛋白表達水平高于對照組(P0.05);進一步分析表明,輕型、重型RAU患者的s PD-1及s PD-L1蛋白表達水平高于對照組(P0.05),而皰疹型RAU患者與對照組無統(tǒng)計學(xué)差異(P0.05)。RAU患者s PD-1表達量與CD19+、C4存在正相關(guān)關(guān)系(r1=0.389,P1=0.034;r2=0.382,P2=0.037)。結(jié)論 RAU患者以細胞免疫功能低下為主,同時伴有體液免疫功能的紊亂;RAU患者s PD-1、s PD-L1蛋白高表達在一定程度上通過影響PD-1/PD-L1信號通路參與RAU免疫機制的調(diào)節(jié),可能在RAU的免疫發(fā)病機制中起著一定作用。
[Abstract]:Objective to investigate the relationship between the expression of soluble programmed death receptor-1 (s-PD-1), soluble programmed death ligand-1 (s PD-L1) protein and immune function in patients with recurrent aphthous ulcer (RAU). To explore the role and significance of s PD-1/s PD-L1 in the pathogenesis of RAU immunity. Methods 30 patients with RAU (mild 18 cases, severe 5 cases, herpes type 7 cases) and 18 healthy subjects (control group) were studied. The immune indexes of peripheral blood cells (CD3, CD4, CD8, CD19, CD16 56) and humoral immune indexes (Ig G, IgE, C3, C 4) in patients with RAU were detected by flow cytometry and scattering turbidimetry respectively. The expression of s PD-1,s PD-L1 protein in serum of RAU patients and healthy people was measured by enzyme linked immunosorbent assay (Elisa), and the correlation between the expression of s PD-1,s PD-L1 and immune function and clinical characteristics of RAU patients was analyzed. Results compared with the normal value, the level of CD4 in patients with RAU decreased, Ig M level, the difference was statistically significant (P 0.05). The expression of s PD-1 and s PD-L1 protein in Rau patients was higher than that in the control group (P 0.05). Further analysis showed that the expression of s PD-1 and s PD-L1 protein in patients with mild and severe RAU was higher than that in the control group (P 0.05). There was no significant difference between the patients with herpes RAU and the control group (P 0.05). There was a positive correlation between the expression of s PD-1 and CD19 and C 4 in Rau patients (R1 鈮,
本文編號:2487792
[Abstract]:Objective to investigate the relationship between the expression of soluble programmed death receptor-1 (s-PD-1), soluble programmed death ligand-1 (s PD-L1) protein and immune function in patients with recurrent aphthous ulcer (RAU). To explore the role and significance of s PD-1/s PD-L1 in the pathogenesis of RAU immunity. Methods 30 patients with RAU (mild 18 cases, severe 5 cases, herpes type 7 cases) and 18 healthy subjects (control group) were studied. The immune indexes of peripheral blood cells (CD3, CD4, CD8, CD19, CD16 56) and humoral immune indexes (Ig G, IgE, C3, C 4) in patients with RAU were detected by flow cytometry and scattering turbidimetry respectively. The expression of s PD-1,s PD-L1 protein in serum of RAU patients and healthy people was measured by enzyme linked immunosorbent assay (Elisa), and the correlation between the expression of s PD-1,s PD-L1 and immune function and clinical characteristics of RAU patients was analyzed. Results compared with the normal value, the level of CD4 in patients with RAU decreased, Ig M level, the difference was statistically significant (P 0.05). The expression of s PD-1 and s PD-L1 protein in Rau patients was higher than that in the control group (P 0.05). Further analysis showed that the expression of s PD-1 and s PD-L1 protein in patients with mild and severe RAU was higher than that in the control group (P 0.05). There was no significant difference between the patients with herpes RAU and the control group (P 0.05). There was a positive correlation between the expression of s PD-1 and CD19 and C 4 in Rau patients (R1 鈮,
本文編號:2487792
本文鏈接:http://sikaile.net/yixuelunwen/kouq/2487792.html
最近更新
教材專著